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ABSTRACT
The term epithelial ovarian cancer refers to a heterogeneous group of tumors, including serous, mucinous, endometrioid 
and clear cell carcinomas, each characterized by specific molecular background and clinical outcome. A growing body 
of evidence suggests that molecular pathogenesis of ovarian cancer involves two general pathways. The first pathway 
results in transformation of normal ovarian tissue to borderline tumors, which may further progress to low-grade serous, 
mucinous, endometrioid and clear cell carcinomas. Type I tumors often harbor somatic mutations in protein kinase genes, 
as well as in genes for other signaling molecules. Both BRAF and KRAS mutations lead to a constitutive activation of their 
downstream target, mitogen-activated protein kinase. Identification of molecular profile may be crucial for the diagnosis 
of ovarian tumors, choice of adjuvant targeted therapy and management of recurrence disease. Point mutations in cancer 
cells can be detected with many various methods. Application of direct sequencing as a routine method for cytological 
diagnosis used in a hospital setting requires expensive equipment and implementation of complicated procedures. Another 
factor limiting application of this method in everyday clinical practice are long analytical times. This stimulated search for 
a simple, rapid, specific and sensitive methodology to detect point mutations. Recently, some new molecular assays for 
the detection of BRAF, KRAS and NRAS mutations have become available. These are fully-automated molecular diagnostic 
systems for quantitative allele-specific RT-PCR-based analyses. Using this instrument, even pathologists from less expe-
rienced laboratories can easily integrate morphological findings with molecular data being crucial for further diagnostic 
and therapeutic decisions.
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INTRODUCTION
Epithelial ovarian cancer (EOC) represents approxima-
tely 90% of all primary ovarian malignancies. The term EOC 
refers to a heterogeneous group of tumors, including serous, 
mucinous, endometrioid and clear cell carcinomas, each 
characterized by specific molecular background and clinical 
outcome. A growing body of evidence suggests that mole-
cular pathogenesis of ovarian cancer involves two general 
pathways [1]. The first pathway results in transformation 
of normal ovarian tissue to borderline tumors, which may 
further progress to low-grade serous, mucinous, endome-
trioid and clear cell carcinomas. Type I tumors often harbor 
somatic mutations in protein kinase genes (KRAS, BRAF, 
PI3KCA and ERRB2), as well as in genes for other signaling 
molecules (e.g. CTNNB1 and PTEN). Tumors from this group 
are characterized by slow proliferation, and approximately 
55% 5-year survival rate [2]. In contrast, type II ovarian tu-
mors are high-grade, highly aggressive malignancies, spre-
ading rapidly throughout the pelvis. This group includes 
high-grade serous carcinoma, malignant mixed mesodermal 
tumors and undifferentiated carcinomas. Many of these 
malignancies harbor mutations in TP53, a tumor suppressor 
gene, and have high proliferative index. It is estimated that 
60% of sporadic ovarian malignancies and most tumors 
found in BRCA1 mutation carriers are high-grade serous 
carcinomas [3].
RAS/mitogen-activated protein kinase (MAPK) and pho-
sphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein 
kinase B (AKT) are two major intracellular signaling trans-
duction pathways, activated due to: loss of phosphatase 
and tensin homolog (PTEN) function, genetic mutations in 
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
693
Paweł Sadłecki et al., Diagnosis in EOC
www. journals.viamedica.pl/ginekologia_polska
subunit α (PI3KCA), Kirsten rat sarcoma viral oncogene ho-
molog (KRAS), neuroblastoma RAS viral oncogene homolog 
(NRAS) or proto-oncogene serine/threonine kinase B-Raf 
(BRAF), or induction of mutations in MET proto-oncogene, 
a member of the receptor tyrosine kinase family being in-
volved in ovarian carcinogenesis [4, 5]. Both BRAF and KRAS 
mutations lead to a constitutive activation (phosphoryla-
tion) of their downstream target, mitogen-activated pro-
tein kinase (MAPK), also referred to as extracellular signal-
-regulated protein kinase (ERK) [6]. Presence of mutations 
in BRAF or KRAS genes co-exists with overexpression of 
activated ERK1/2 in ovarian serous tumors. Upregulation of 
ERK1/2 results in activation of downstream cellular targets, 
including a variety of cellular and nuclear proteins [7]. Ho-
wever, biological role of this pathway in the development 
of ovarian malignancies other than serous ovarian cancer 
is still not completely understood.
Identification of molecular profile may be crucial for 
the diagnosis of ovarian tumors, choice of adjuvant tar-
geted therapy after primary cytoreductive treatment, or 
management of recurrence in patients with advanced type 
I epithelial ovarian neoplasms.
LOW-GRADE SEROUS OVARIAN CANCER
Low-grade serous ovarian cancer (LGSC) is characterized 
by young age at diagnosis, indolent course, and longer 
overall survival than in the case of high-grade serous ova-
rian cancers (HGSCs), even at more advanced stages [2]. 
LGSCs represent less than 10% of serous ovarian cancers and 
are less sensitive to conventional platinum-based chemo-
therapy than HGSCs [8]. They are characterized by relative 
nuclear uniformity, lack of nuclear pleomorphism, and mi-
totic activity no greater than 12 mitoses per 10 high-power 
fields. Under a microscope, LGSCs typically present as mi-
cropapillae surrounded by clear spaces; however, glandular, 
macropapillary and single cell patterns can also be seen 
(Fig.  1) [9]. LGSCs are believed to arise from preexisting 
cystadenomas or serous borderline tumors (SBTs) that even-
tually progress to an invasive carcinoma. While the majority 
of typical SBTs do not have a typical phenotype of invasi-
ve carcinoma, microinvasion is not uncommon. In some 
studies, up to 60% LGSCs were associated with SBTs [10]. 
Although HGSCs and LGSCs share some characteristics, they 
have also some distinct immunophenotypic features. Both 
tumor types express paired box gene 8 (PAX8) and WT1, as 
well as estrogen (ER) and progesterone receptors (PR) [9]. 
LGSCs are characterized by patch p16 staining pattern, wild-
-type p53 staining pattern, and low Ki-67 proliferative index 
[11]. More than 60% of LGSCs harbor MAPK pathway-acti-
vating KRAS or BRAF mutations (occurring with a similar 
frequency of ca. 30%); mutations in HER2 have been also 
reported [12]. Both Grisham and Wong reported that women 
with mutations in KRAS and/or BRAF had better prognosis 
than those without. This phenomenon can be at least par-
tially explained by the results of previous studies. SBTs from 
women with BRAF mutations were shown to over-express 
genes with cell growth inhibitory effects [13]. Furthermore, 
activating BRAF mutations were postulated to induce cellu-
lar senescence and to prevent progression of SBTs to LGSCs 
[14]. On the other hand, Singer reported that presence of 
KRAS mutation may be associated with more aggressive, 
recurrent phenotype of LGSC than the one observed in 
BRAF mutation carriers [15]. It should be emphasized that 
presence of KRAS mutation in a given tumor excludes exi-
stence of a concomitant BRAF mutation, and vice versa [15]. 
ENDOMETRIOID OVARIAN 
ADENOCARCINOMA
Endometrioid ovarian adenocarcinoma (EC) is usually 
associated with endometriosis or endometrioid adenofi-
broma/borderline tumor. It typically presents as a unilateral 
mass confined to the ovary. In most cases, EC is diagnosed 
based on the presence of back-to-back glands, rather than in-
filtrative invasion [9]. EC has several characteristic histologic 
features, such as squamous morules, mucinous differentia-
tion, clear cell change, spindle-shaped morphology and 
secretory change, although the latter may sometimes raise 
a suspicion of clear cell carcinoma (Fig. 2) [9]. EC should be 
primarily differentiated from metastatic colonic adenocar-
cinoma; differential diagnosis can be based on immuno-
histochemistry, since EC is positive for cytokeratin 7 (CK7), 
PAX8, ER and PR, whereas colonic adenocarcinoma tests 
positively for cytokeratin 20 (CK20) and caudal-type home-
obox 2 (CDX2) protein. However, it should be remembered 
that the expression of CDX2 may be also found in squamous 
morules forming EC [16]. Distinguishing high-grade EC from 
a high-grade serous carcinoma (HGSC) may be challenging, 
especially in the case of predominantly solid tumors. In such 
cases, immunostaining for WT1, p53 and p16 is an option; 
usually, HGSCs give strong and diffuse positive reaction with 
these markers, whereas ECs are negative for WT1, show patch 
Figure 1. Microphotograph presenting H&E stained specimens of low 
grade serous ovarian cancer, primary objective magnification 20×
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p16 staining pattern and wild-type p53 staining pattern [17]. 
Approximately 10% of patients with ovarian cancers pre-
sent with synchronous endometrial tumors [18], metastases 
from the ovary or endometrium, or synchronous primary 
ovarian or endometrial tumors. Soliman et al. found that 
patients with synchronous endometrial and ovarian prima-
ries had distinct clinical characteristics, such as younger age, 
nulliparity, obesity and premenopausal status [18]. Overall 
survival in subjects with synchronous primaries is usually 
excellent (approximately 10 years), especially if both tu-
mors had endometrioid histology. Ovarian ECs are typically 
associated with somatic mutations in catenin β1 (CTNNB1) 
and PTEN genes [19]. The frequency of CTNNB1 abnormali-
ties in ovarian and endometrial ECs is essentially the same, 
but the former less often show microsatellite instability and 
PTEN alterations. In rare cases, a low-grade EC may co-exist 
with an adjacent undifferentiated carcinoma; this type of 
malignancy is referred to as de-differentiated carcinoma, 
and can be often misdiagnosed as EC, FIGO grade 3. De-dif-
ferentiated carcinoma was first described by Silva et al.; these 
authors demonstrated that presence of an undifferentiated 
carcinoma component of any size in ovarian or endometrial 
endometrioid carcinoma is associated with markedly worse 
prognosis [20]. In the ovaries, de-differentiated carcinomas 
may represent the far end of the HGSC spectrum or be as-
sociated with low-grade ECs. Undifferentiated carcinoma 
is composed of discohesive, monotonous cells resembling 
lymphoma. Identification of specific morphologic features 
of these tumors is vitally important, especially if they co-
-exist with low-grade ECs, since as already mentioned, such 
combination is associated with a significantly worse progno-
sis. Although undifferentiated carcinomas can express some 
neuroendocrine markers, proportion of these tumors with 
a positive result of immunostaining is less than 10%. Diffuse 
pattern of immunostaining for neuroendocrine markers favors 
diagnosis of a high-grade neuroendocrine carcinoma [21]. 
EC has an excellent prognosis, especially when confined 
to the ovary. In adequately staged patients, an acceptable 
therapeutic strategy can be even a watchful waiting.
MUCINOUS OVARIAN CANCER
Mucinous ovarian cancer is a rare histological type, re-
presenting 2–4% of all epithelial ovarian carcinomas [22]. 
Mucinous tumors have a multicystic structure with more 
than 90% of cells filled with conspicuous amounts of mucin 
(usually occupying ≥ 50% of the cytoplasm) [22]. Origin 
of mucinous tumors still raises some controversies. Many 
malignancies from this group that were previously classified 
as primary tumors, are nowadays considered misdiagnosed 
metastases from other locations, primarily from the ga-
strointestinal tract and endocervix (Fig. 3) [23]. Mucinous 
ovarian tumors are postulated to arise from benign lesions, 
which transform to mucinous borderline tumors and then, 
to the invasive forms. The majority of them are mucinous 
borderline tumors (MBOTs) or stage I mucinous carcinomas 
(MCs). Although prognosis is generally excellent, in rare ca-
ses with extra-ovarian spread, the outcomes and response 
to conventional chemotherapy may be poor. Aside from sha-
ring many biomarkers with pancreatic and gastrointestinal 
adenocarcinomas, MCs have also similar morphology; the-
refore, differentiating between primary ovarian tumors and 
metastatic disease may sometimes pose a challenge [24]. 
Primary mucinous ovarian carcinomas differ from other 
epithelial ovarian cancers in both presentation and outco-
me [25]. A number of features shared by mucinous tumors, 
among them a dominance of RAS-activating changes, ra-
ises hopes for the development of targeted therapeutic 
strategies dedicated to women with advanced or recurrent 
disease [26]. The most common genetic defects found in 
mucinous tumors are abnormalities of mitogen activated 
protein kinase (MAPK) pathway, especially mutations of 
KRAS genes and amplification/overexpression of ERBB2 [26]. 
Evidence from previous studies suggests that prognosis in 
mucinous ovarian cancers without a known alteration of 
RAS-pathway may be unfavorable, likewise in low-grade 
serous/serous borderline ovarian tumors [27]. According to 
literature, more than 75% of mucinous ovarian tumors may 
harbor KRAS mutations; however, it should be remembered 
that authors of some of these reports did not differentiate 
Figure 2. Microphotograph presenting H&E stained specimens 
of endometrioid ovarian adenocarcinoma, primary objective 
magnification 20×
Figure 3. Microphotograph presenting H&E stained specimens of 
mucinous ovarian cancer, primary objective magnification 20×
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between MBOTs and MCs, and/or did not exclude metastatic 
lesions from mutational status analysis [28]. The results of 
copy number analysis imply that development of mucinous 
tumors may be associated with the loss of heterozygosity 
of chromosomal regions 9p, 17p and 21q. Also other mu-
tated genes, BRAF, TP53, PTEN, PI3KCA, and more recently 
also CDKN2A and RNF43, have been found in tumors from 
this group. However, the rarity of mucinous ovarian tumors 
markedly hinders the possibility of large-scale mutational 
frequency analyses [29].
CLEAR CELL OVARIAN CANCER
Clear cell ovarian cancer (CCC) represents 5–13% of all 
epithelial ovarian malignancies [2]. CCCs are usually diagno-
sed at a younger age than high-grade serous epithelial ova-
rian cancers. They usually present as a pelvic mass confined 
to the ovary, often co-existing with endometriosis (Fig. 4) [30]. 
CCCs have an aggressive clinical phenotype and rarely 
respond to standard platinum-based chemotherapy; due 
to such characteristics, prognosis in CCC is worse than in 
HGSC [31]. Recent evidence suggests that approximately 
40% of these tumors test positively for PI3KCA mutations, 
which implies that their pathogenesis may involve some 
aberrations in telomere biology [32]. The majority of CCCs 
express wild-type p53, rarely harbor germline mutations 
in BRCA 1 and BRCA 2, and show low level of chromosomal 
instability [33]. Another characteristic feature of CCCs is high 
level of hypoxia inducible factor 1 alpha (HIF1a) [34]. The 
proportion of CCCs expressing HER2/neu is 2.5- to 10-fold 
higher than in the case of type I and II ovarian tumors, which 
points to a potential role for HER2/neu inhibitors in treat-
ment of these malignancies. Published data documenting 
KRAS mutational status of CCCs are generally sparse and 
inconclusive [35]. Jones and Auner et al. detected KRAS 
mutations in 4.7% and 26% of CCCs, respectively [36, 37]. 
In contrast, Rechsteineret al. found no mutations of this 
gene in a large cohort of CCC patients [38]. According to De-
spierre et al., mutations of KRAS are present in 14% of CCCs, 
which is markedly lower proportion than in other subtypes 
of ovarian carcinomas, especially mucinous tumors [39]. 
Similar frequency of KRAS mutations was reported for ova-
rian endometrioid carcinomas (7%), which supports the 
hypothesis about a common origin of these two tumor 
types [39]. According to Zannoni et al., KRAS mutations 
found in CCCs are located in codon 12, exon 2, but not in 
codon 13, exon 2 [40].
Determination of BRAF,  
KRAS and NRAS mutation status
Molecular analysis of cancer-causing mutations and de-
velopment of targeted biological therapies constitute a mile-
stone in diagnosis and therapy of ovarian malignancies. Until 
a few years ago, classification of cancers was based primarily 
on the type of tissue they arose, histopathological and clinical 
characteristics. However, more recently, oncological diagnosis 
has been also expanded by including molecular features of 
cancer cells. Usually, molecular tests become a component of 
routine patient care if detection of a specific alteration may 
have impact on diagnosis and/or prognosis, or whenever 
a targeted biological therapy is available.
Point mutations in cancer cells can be detected with many 
various methods. KRAS, NRAS and BRAF mutational status 
can be determined by direct sequencing, which can detect 
all potential variations, including base substitutions, inser-
tions and deletions. However, direct sequencing has some 
limitations when applied to clinical samples. First of all, it is 
not sensitive enough (10–30%) to detect specific point muta-
tions. Analytic sensitivity of this method can be improved by 
pyrosequencing, high-resolution melting analysis, real-time 
or allele-specific PCR assays. Next-generation sequencing me-
thods provide high analytic sensitivity, offer broad reportable 
range of mutation spectrum, and have adequate capacity for 
quantitative measurement of mutant allele frequencies and 
simultaneous detection of concomitant mutations [41, 42].
Application of direct sequencing as a routine method 
for cytological diagnosis used in a hospital setting requires 
expensive equipment and implementation of complica-
ted procedures. Another factor limiting application of this 
method in everyday clinical practice are long analytical 
times. This stimulated search for a simple, rapid, specific and 
sensitive methodology to detect point mutations. Recen-
tly, some new molecular assays for the detection of BRAF, 
KRAS and NRAS mutations have become available (Fig. 5). 
These are fully-automated molecular diagnostic systems for 
quantitative allele-specific RT-PCR-based analyses. Unlike 
currently available technologies, IdyllaTM Mutation Test does 
not require manual preprocessing of the sample (depa-
raffinization, digestion of FFPE tissue or DNA extraction), 
since all these procedures are integrated within a single-use 
cartridge. Instead, whole FFPE tissue sections or macro-dis-
sected FFPE specimens are inserted into the cartridge and 
Figure 4. Microphotograph presenting H&E stained specimens of 
clear cell ovarian cancer, primary objective magnification 20×
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processed by the IdyllaTM system; also further stages, i.e. real-
-time PCR-based mutation detection and result reporting, 
are fully-integrated and automated [43]. Without the need 
for highly-skilled staff, mutational tests approved by the 
European Community for in vitro diagnostic use (labeled 
as CE-IVD) can genotype KRAS, BRAF and NRAS with a high 
detection limit, and therefore, can be used as a standardized 
method, even at diagnostic centers without a developed 
molecular infrastructure [44]. Using this instrument, even 
pathologists from less experienced laboratories can easily 
integrate morphological findings with molecular data being 
crucial for further diagnostic and therapeutic decisions.
CONCLUSIONS
In recent years, a plethora of compounds targeting com-
ponents of RAS-RAF-MEK pathway entered clinical trials, 
and some of them have already demonstrated a promi-
sing clinical activity. Beneficial effects of targeted therapies 
may be associated with inhibition of downstream signaling 
pathways, primarily RAS-RAF-MAPK and PI3K-PTEN-AKT. 
Introduction of personalized therapies has revolutionized 
standards of care in selected cases; detection of a critical 
somatic mutation in cancer cells improves diagnostic and 
prognostic accuracy, but first of all, may guide the selection 
of a highly-effective targeted therapy, producing not only 
health but also economic benefits.
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